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Abstract
Background: Neurocysticercosis (NCC) is the most common cause of acquired epilepsy in Taenia solium endemic areas,
primarily situated in low-income countries. Diagnosis is largely based upon the ‘‘Del Brutto diagnostic criteria’’ using the
definitive/probable/no NCC diagnosis approach. Neuroimaging and specific T. solium cysticercosis antibody detection
results are at the mainstay of this diagnosis, while antigen detection in serum has never been included. This study aimed at
evaluating the addition of antigen detection as a major diagnostic criterion, especially in areas where neuroimaging is
absent.
Methods: The B158/B60 monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) for the detection of
circulating cysticercus antigen was carried out retrospectively on serum samples collected during a hospital-based study
from 83 people with epilepsy (PWE) in an endemic area.
Results: The addition of antigen results as a major criterion allowed the correct diagnosis of definitive NCC in 10 out of 17
patients as opposed to 0/17 without antigen results in the absence of neuroimaging. A sensitivity of 100% and a specificity
of 84% were determined for the diagnosis of active NCC using antigen ELISA. While the use of a higher cutoff improves the
specificity of the test to 96%, it decreases its sensitivity to 83%.
Conclusions: In areas where neuroimaging is absent, NCC diagnosis according to the existing criteria is problematic. Taking
into account its limitations for diagnosis of inactive NCC, antigen detection can be of added value for diagnosing NCC in
PWE by supporting diagnostic and treatment decisions. Therefore, we recommend a revision of the ‘‘Del Brutto diagnostic
criteria’’ for use in resource poor areas and suggest the inclusion of serum antigen detection as a major criterion.
Citation: Gabrie¨l S, Blocher J, Dorny P, Abatih EN, Schmutzhard E, et al. (2012) Added Value of Antigen ELISA in the Diagnosis of Neurocysticercosis in Resource
Poor Settings. PLoS Negl Trop Dis 6(10): e1851. doi:10.1371/journal.pntd.0001851
Editor: Philip J. Cooper, Universidad San Francisco de Quito, Ecuador
Received January 25, 2012; Accepted August 23, 2012; Published October 18, 2012
Copyright:  2012 Gabrie¨l et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by The Savoy Epilepsy Foundation, Quebec, Canada, and ASW was supported by The Center for International Migration,
Frankfurt, Germany. The publication fees in an open access journal were covered by the Deutsche Forschungsgemeinschaft and Open Access Publication Funds of
Go¨ttingen University Medical Centre (UMG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Joachim.blocher@med.uni-goettingen.de
. These authors contributed equally to this work.
Introduction
More than 80% of people with epilepsy (PWE) live in low-
income countries [1], where the prevalence of active epilepsy is
approximately twice that of high-income countries [2]. Moreover,
in many of those countries over 75% of PWE have no access to
treatment with anti-epileptic medication [3].
Infectious diseases play a major role in the etiology of epileptic
seizures and epilepsy in developing countries [1]. A recent review
reported that 29% of PWE also had neurocysticercosis (NCC) [4],
caused by the larval stage of Taenia solium, a zoonotic parasite.
The treatment of NCC depends on the stage of the disease and
the number and localization of lesions. The determination of an
optimal treatment is still a developing field of research, it may have
to be tailored to individual cases and relies largely on results of
neuroimaging techniques. However, there is frequently no or very
limited access to/availability of these neuroimaging tools in low-
income endemic countries.
To assist in diagnosis, a number of immunodiagnostic tests have
been developed, among which is the enzyme-linked immunoelec-
trotransfer blot (EITB) that detects specific antibodies against T.
solium cysticerci in serum and was reported to have a high
specificity (100%) and sensitivity (98%) [5,6]. This test is widely
recognized; unfortunately it is expensive and in a format (Western
Blot) not very applicable in most resource-poor laboratories in
endemic areas. More field applicable enzyme-linked immunosor-
bent assay (ELISA) formats have been developed to detect specific
antibodies and antigens in the serum, although they have until
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now failed to produce consistently good results of high specificity
and high sensitivity [6]. However, research is ongoing into the
development/identification of new markers for diagnostic tools [7–
9]. The current antigen detecting ELISA’s are based on
monoclonal antibodies that detect excretory/secretory proteins
produced by viable cysts [10,11]. As such, these tests detect viable
cysts only, which has several epidemiological and clinical
implications. In epidemiological studies, the presence of antigens
indicates presence of infection, whereas presence of antibodies
indicates exposure to the parasite, but not necessarily establish-
ment of infection [12]. For the B158/B60 monoclonal antibody-
based antigen ELISA a sensitivity of 90% (95% CI: 80%–99%)
and a specificity of 98% (95% CI: 97%–99%) were determined for
the detection of infected individuals, based on Bayesian analyses
[12].
Currently, the only published diagnostic criteria are the ‘‘Del
Brutto diagnostic criteria’’ [13]. However, these criteria have not
been systematically validated [14]. Neuroimaging and EITB
results provide the basis for most absolute and major criteria,
while antigen detection in serum has never been included in the
criteria.
The aim of this study was to determine the added value of
specific antigen detection in the diagnosis of NCC related epilepsy.
Detection of circulating T. solium cysticercosis antigen was
performed retrospectively on samples from PWE obtained from
a hospital-based study carried out in northern Tanzania, in which
clinical examinations, CT scanning and antibody detection had
been carried out [15–17].
Materials and Methods
Ethical statement
The study and the use of human subjects for the study were
approved by the National Institute for Medical Research (NIMR),
Tanzania. The samples were anonymized and transported in
accordance to a material transfer agreement between HLH,
NIMR, the Medical University Innsbruck, CDC, and ITM.
Written informed consent was obtained from all participants or
legal custodians in case of minors. PWE received free treatment for
epilepsy and, in case of active NCC, anthelmintic treatment
according to national guidelines.
Recruitment of participants
The study took place at Haydom Lutheran Hospital (HLH)
situated in a remote area in the North of Tanzania. The serum
and CSF samples were collected during a hospital-based study that
has been described elsewhere [15–17]. Briefly, 212 PWE, all above
10 years of age, diagnosed by a neurologist (ASW) were followed
up and computer tomography (CT) scans were performed.
Epilepsy was defined as two or more unprovoked epileptic seizures
and categorized according to an International League Against
Epilepsy adjusted classification for resource-poor countries [18].
Venous blood samples were taken from 83 of the 212 examined
PWE, including 28 of 29 PWE with highly suggestive or definite
NCC lesions on CT scan, 7 of 9 PWE with lesions compatible with
NCC and 48 of 126 without NCC lesions on CT scan. Due to
ethical reasons it was not possible to take blood from all PWE. In
addition 11 CSF samples from PWE with multiple cysts or
calcifications on CT scan were collected.
Diagnosis of neurocysticercosis
The diagnosis of NCC was based on the diagnostic criteria
proposed by Del Brutto et al. (2001) [13]. The combination of
absolute, major, minor and epidemiological criteria lead to the
diagnoses of definitive, probable or no NCC (Annex S1). All
participants had an epidemiological criterion, because Tanzania is
endemic for cysticercosis [19]. Epilepsy is a clinical manifestation
suggestive of NCC; hence all PWE had one minor criterion. In the
present study, CT scans with contrast were available from all
PWE. The CT scanner was a Toshiba Auklet Slice Spiral CT. The
thickness of slices was 5 mm at skull base and 10 mm above the
skull. Cystic lesions showing the scolex were regarded as an
absolute criterion, multiple parenchymal calcifications and ring
enhancing lesions, which are highly suggestive of NCC, as a major
criterion and lesions that are compatible with NCC including
equivocal single parenchymal calcifications as a minor criterion
(Annex S1). Cystic and ring enhancing lesions were regarded as
active NCC and calcifications only as inactive NCC.
Collection and analysis of serum and cerebrospinal fluid
samples
All samples were collected between May and August 2006 at
HLH. After clotting, blood samples were centrifuged at 10006/
min for 5 minutes and serum was separated. All samples were
initially kept at 4–8uC and after transport in September 2006 at
220uC. The Centers for Disease Control and Prevention, Atlanta,
USA (CDC) performed the CDC-developed EITB [5]. Results of
the latter analysis were published previously [16].
Samples were analyzed using the B158/B60 antigen ELISA
(Ag-ELISA) at the Department of Biomedical Sciences of the
Institute of Tropical Medicine, Antwerp, Belgium (ITM) [20].
Eight negative and 2 positive control serum samples were run on
each plate. The plates were read using an automated spectropho-
tometer at 490 nm with a reference of 655 nm. The optical
density (OD) of each serum sample was compared with a sample of
negative serum samples (n = 8) at a probability level of p = 0.001
(cut-off calculation). A ratio for each sample was calculated by
dividing the mean OD of the sample (samples were tested in
duplicate) by the cut-off [21]. These ratios were used in the
Receiver Operating Characteristic analysis (see data analyses).
CSF samples were run using the same methodology and cut-off
calculation, albeit the pre-treatment of samples with trichloroace-
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tic acid was not carried out. CSF samples were diluted K in
phosphate buffered saline.
Data analysis
The evaluation of the accuracy of Ag-ELISA was performed
using a Receiver Operating Characteristic (ROC) analysis. This was
done using ‘‘probable and definitive NCC’’ versus ‘‘no NCC’’ and
‘‘active’’ versus ‘‘inactive and no NCC’’ as reference tests (as
determined by the ‘‘Del Brutto diagnostic criteria’’) each in turn.
The optimal cut-off ratio value was selected as the point on the
ROC curve (which displays estimated percentages of sensitivity and
specificity at a selected cut-off value) with the minimum distance to
the (0, 1) coordinate. The ROC curves were generated using the R
software package [22]. The Fisher’s exact test was used to compare
circulating antigen levels in different diagnostic groups. Statistical
significance was arbitrated at the 5% level. The Mann-Whitney U
test was used to compare two groups in a non parametric variable.
Results
General aspects
Of the 83 PWE in whom antigen testing was performed, 34 were
diagnosed with NCC (following the ‘‘Del Brutto diagnostic criteria’’), of
which 17 were cases of definitive NCC and 17 of probable NCC. Six
out of the 17 definitive NCC cases had active NCC lesions on CT scan.
About twenty seven percent (22/83) of PWE were positive on
serum Ag-ELISA. In the group of PWE with NCC (according to the
‘‘Standard Del Brutto Diagnostic criteria’’), circulating antigens were
detected in 44.1% (15/34); 58.8% (10/17) in people with definitive
NCC and 29.4% (5/17) in people with probable NCC. In the group
of PWE without NCC, 14.3% (7/49) were positive on serum Ag-
ELISA. The difference in proportion between PWE with NCC and
PWE without NCC appeared to be statistically significant (p=0.005,
Fisher’s exact test).
In the group of people with NCC, 100% of active NCC cases
(6/6) had a positive Ag-ELISA result in serum, which was
significantly higher compared to people with inactive lesions, in
whom 33.3% (8/24) were positive on antigen detection (p = 0.005,
Fisher’s exact test) (Figure 1).
The number of NCC lesions (active or inactive) was significantly
associated with a positive Ag-result (p = 0.009, Mann-Whitney U).
Four out of eleven (36.4%) CSF samples were positive on Ag-
ELISA. All patients with a positive result based on CSF were also
positive based on serum. Regarding diagnosis of NCC, all people
with probable NCC were negative on CSF Ag-ELISA (0/5) and
66.7% (4/6) with definitive NCC were positive. Whereas all
samples from people with active NCC (4/4) were positive, all
samples from people with inactive NCC were negative (0/7).
Neuroimaging
In Table 1, a comparison is made between different types of
NCC lesions and circulating antibody and antigen results in serum
and CSF.
Del Brutto diagnostic criteria
In Table 2, the ‘‘Standard Del Brutto diagnosis’’ ( = using
neuroimaging, EITB, clinical, serological and epidemiological
data; annex S1) is compared with the Del Brutto diagnosis without
neuroimaging and 1) only EITB is used as a major criterion; 2)
only Ag-ELISA is used as a major criterion; 3) EITB and Ag-
ELISA are used as major criteria. In the last row, we have
determined the change of diagnosis using the ‘‘Standard Del
Brutto diagnosis’’ with Ag-ELISA as an added major criterion.
The 83 PWE from our study are according to the ‘‘Standard
Del Brutto diagnosis’’, divided into 17 cases of definitive NCC, 17
of probable and 49 of no NCC. In the absence of neuroimaging,
and if only EITB was considered as a major criterion, the 17 cases
of definitive NCC could only be diagnosed as probable NCC. If
Figure 1. Neurocysticercosis diagnosis according to Del Brutto et al. (2001)22 and percentage antigen ELISA positivity. Shaded boxes
indicate the ‘‘Del Brutto diagnoses’’ (except for *), non-shaded boxes indicate the number and percentage of antigen positive cases.
NCC=neurocysticercosis, Ag pos = antigen ELISA positivity, CSF= cerebrospinal fluid, PWE=people with epilepsy. *Active, inactive or no lesions
according to CT scan results.
doi:10.1371/journal.pntd.0001851.g001
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Ag-ELISA was the only major criterion (in absence of EITB results
and neuroimaging), 10 cases would be diagnosed as probable
NCC and the others as no NCC. If considering both EITB and
Ag-ELISA as major criteria, 10 cases would be diagnosed as
definitive NCC and 7 as probable NCC.
Of the 17 cases with probable NCC only 6 and 5 cases can be
diagnosed with EITB and Ag-ELISA as only majors, respectively.
When combining both tests, 3 diagnoses of definitive NCC are made.
When all criteria are considered, with inclusion of Ag-ELISA (last
row in the Table), 5 cases are allocated a diagnosis of definitive NCC.
In the group of 49 cases with no NCC diagnosis, the addition of
Ag-ELISA as a criterion yields 7 probable NCC diagnoses.
Antigen-ELISA for the detection of neurocysticercosis in
people with epilepsy
In Figure 2, the ROC curve shows the relationship between
sensitivity and the complement of specificity for Ag-ELISA for the
detection of NCC in PWE. The dot on the curve indicates the
optimal cut-off value corresponding to the maximum sensitivity
and specificity (shortest distance to the point (0,1) in the diagram).
The optimal cut-off ratio value of 0.81 corresponded to an
estimated sensitivity of 53% (95% CI: 37–69%), specificity of 71%
(95% CI: 58–82%). The area under the curve was 0.63 (95% CI:
0.52–0.75). If a maximum specificity is requested, an optimal cut-
off ratio value of 1.08 can be used, with a sensitivity of 44% (95%
CI: 29–61%) and a specificity of 90% (95% CI: 78–96%).
Antigen-ELISA for the detection of active
neurocysticercosis in people with epilepsy
In Figure 3, the ROC curve shows the relationship between
sensitivity and the complement of specificity for Ag-ELISA for the
detection of active NCC in PWE. The optimal cut-off ratio value
of 1.17 corresponded to an estimated sensitivity of 100% (95% CI:
61–100%), specificity of 84% (95% CI: 75–91%) and the area
under the curve was 0.95 (95% CI: 0.90–1). Considering a
prevalence of active NCC of 7.2% (6/83) in our group of PWE, a
positive predictive value of 33% and negative predictive value of
100% can be calculated.
If a maximum specificity is requested, an optimal cut-off ratio
value of 39.97 can be used, with a sensitivity of 83% (95% CI: 44–
97%) and a specificity of 96% (95% CI: 90–99%). At this cut-off
ratio, a positive predictive value of 63% and negative predictive
value of 99% can be calculated.
Discussion
The availability of good diagnostic tests for neurocysticercosis
(NCC) is essential not only for diagnosis and treatment of
individuals, but also for epidemiological studies needed to
determine disease burden and evaluation of control programs.
In general, diagnosis of NCC is based on the ‘‘Standard Del Brutto
diagnostic criteria’’ [13], which are primarily built on neuroim-
aging. Unfortunately, in most endemic areas, access to neuroim-
aging is very limited or absent. Therefore, there is an urgent need
to assess the validity of these diagnostic criteria in resource-poor
areas, and to determine how they can be improved. The aim of
this study was to determine the added value of specific antigen
detection in the diagnosis of NCC related epilepsy in resource
poor settings.
Results indicate a high percentage of antigen positive sera in
PWE with active NCC (100% positive), definitive NCC (58.8%)
and probable NCC (29.4%), while the percentage is clearly lower
in PWE without NCC (14.3%).
These results suggest that circulating antigen detection in serum
can be a valuable aid for the diagnosis of NCC. However until
now, according to the ‘‘Del Brutto diagnostic criteria’’ [13],
antigen detection in serum is not a criterion at all. We have
evaluated what effect the addition of serum antigen results as a
major criterion would have on NCC diagnosis, in comparison with
the ‘‘Standard Del Brutto diagnostic criteria’’, especially if
neuroimaging techniques are not available.
‘‘Standard Del Brutto diagnostic criteria’’ and Ag-ELISA
Definitive neurocysticercosis. In the absence of neuroim-
aging, no definitive diagnosis could be made in this study. The use
of both EITB and Ag-ELISA as major criteria permits a definitive
diagnosis without neuroimaging, as this would yield two major,
one minor and one epidemiological criteria according to the ‘‘Del
Brutto diagnostic criteria’’ (Annex S1). In our study, this would
allow us to diagnose 10 of the 17 patients with definitive NCC
(Table 2, d), while with only EITB results at our disposition, we
would not be able to determine a definitive diagnosis at all.
When applying only Ag-ELISA results (in the absence of EITB)
as major criterion, 7 cases of definitive NCC remain with a no NCC
diagnosis (Table 2, a). All these are cases of inactive NCC, which
means that no viable cysts were detected on CT scan. This can
explain the negative Ag-ELISA result leading to a no NCC
diagnosis.
Table 1. Neurocysticercosis lesions on cerebral CT scan, antigen ELISA and EITB results in serum and cerebrospinal fluid.
Neuroimaging EITB (Serum) EITB (CSF)
Absolute
NCC
Highly
suggestive
NCC
Compatible
NCC No NCC pos neg pos neg
N6 of active NCC 5 1 0 0
Ag-ELISA pos 5 (100%) 7 (30.4%) 2 (28.6%) 8 (16.7%) 13 (56.5%) 9 (15.5%) 4 (80%) 1 (16.7%)
(serum) neg 0 (0%) 16 (69.6%) 5 (71.4%) 40 (83.3%) 10 (43.5%) 49 (84.5%) 1 (20%) 5 (83.3%)
Ag-ELISA pos 3 (100%) 1 (12.5%) n/a n/a 4 (66.6%) 0 (0%) 4 (80%) 0 (0%)
(CSF) neg 0 (0%) 7 (87.5%) n/a n/a 2 (33.3%) 5 (100%) 1 (20%) 6 (100%)
NCC= neurocysticercosis,
EITB = enzyme-linked immunoelectrotransfer blot detecting specific antibodies against T. solium cysticerci,
Ag-ELISA = B158/B60 monoclonal antibody-based enzyme-linked immunosorbent assay.
CSF = cerebrospinal fluid.
doi:10.1371/journal.pntd.0001851.t001
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Probable and no neurocysticercosis. When considering
the Ag-ELISA as a major criterion in the probable NCC diagnosis
group, similar results as with the EITB are obtained.
The additional 7 probable NCC diagnoses in the no NCC
group (Table 2, c) and additional 3 (5 if neuroimaging is also
included) definitive diagnoses in the probable NCC group, all
due to Ag-ELISA positivity, could not be confirmed on
neuroimaging (Table 2, b). The neuroimaging technique used
in this study was CT scan, which is known to have a lower
sensitivity for the diagnosis of viable cysts compared to MRI.
As such, the presence of viable cysts – as indicated by Ag-
ELISA – could have been missed on CT scan [23–25]. False
positive results due to cross reactions should be considered as
well, though no cross reactions were observed when examin-
ing sera from patients with parasitologically and/or serolog-
ically confirmed infections with Schistosoma, hydatid cysts,
Ascaris, Trichuris, filaria, Entamoeba, Plasmodium and Trypanosoma
[26]. Alternatively, the Ag-ELISA may cause an overestima-
tion of NCC cases, as positive results may be due to viable
cysts lodging elsewhere in the body. The latter is a
complicating factor for both serological tests (EITB and Ag-
ELISA), as they cannot indicate the position of the cysts in the
body. Analyzing CSF could be a helpful tool to localize cysts
within the central nervous system. A recent study indicates a
significant relationship between antigen levels in CSF and
total number of lesions as well as number of non-degenerating
cysts as identified by MRI [27]. In our study, all patients with
viable cysts on CT scan had a positive CSF Ag-ELISA and all
patients with only calcified lesions had a negative result.
Therefore CSF analysis might be a useful tool for localizing
the infection. However, our sample size was too small to draw
a valid conclusion and further studies are needed to confirm
these interesting results.
Taking the limitations in the case of inactive NCC into
consideration, we strongly believe that the Ag-ELISA has an
important added value in NCC diagnosis, especially as it
permits a definitive diagnosis based on serological results
(EITB and Ag-ELISA), without neuroimaging. Therefore, a
revision of the ‘‘Del Brutto diagnostic criteria’’ could be
considered towards including the serum Ag-ELISA as a major
criterion. The format of the Ag-ELISA is cheap and needs little
equipment. It is a monoclonal antibody based test that does
not require a continuous supply of fresh parasite material.
Moreover, the format has the potential to be adapted into a
commercial rapid ELISA kit or lateral flow device. This would
make the test more applicable in poorly equipped laboratories
with limited financial resources.
Ag-ELISA and extraparencymal NCC
A less frequent, but nevertheless important manifestation of
NCC is extraparenchymal NCC. Due to the design of our
study, which included only patients with epilepsy, most of our
patients had parenchymal cysts and our results cannot be
extrapolated to people with extraparenchymal NCC. However,
using the ‘‘Del Brutto diagnostic criteria’’ might lead to an
underestimation of Cysticercus racemosus forms, because a scolex
is not visible [28]. Here also, serum circulating antigen
detection could possibly be of great value, as racemose cysts
are easily detectable by Ag-ELISA [29].
Ag-ELISA and implications for clinical diagnosis and
treatment
Presence or absence of live cysts can influence treatment
decisions as it has consequences on the use of anthelminthics. In
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the absence (availability and/or access) of neuroimaging, antigen
detection could be important to guide further diagnostic and
treatment decisions, although treatment with anthelminthic
medication based on positive serology results alone clearly is not
advisable in resource-poor settings. Furthermore, antigen detec-
tion is considered helpful to follow up patients after treatment,
where a relatively fast decrease in antigen levels is expected in
contrast to antibody levels that can remain positive up to one year
after treatment [30].
Clearly the use of the Ag-ELISA to identify NCC cases in a
population of PWE (NCC versus no NCC) is less efficient as for
the identification of active NCC cases. This can be explained by
the number of inactive NCC cases, which the test cannot identify
as it detects viable cysts only. However, clinically the differenti-
ation between active NCC and inactive/no NCC is more
important than between NCC and no NCC, because the presence
or absence of live cysts will influence treatment decisions. Whereas
PWE with active NCC should receive antiepileptic drugs, steroids
and, depending on number and location of cysts visible on
neuroimaging, anthelminthic treatment or even surgery, PWE
with inactive or without NCC only need antiepileptic drugs [31].
Positive Ag-ELISA in PWE may help decide in resource-poor
settings whether the patient absolutely needs neuroimaging or not,
which justifies transportation of the patient to the nearest hospital
with neuroimaging facilities.
In conclusion, our results indicate that T. solium cysticercosis
antigen detection can be of added value for diagnosis of NCC in
PWE. As such, besides its use in epidemiological studies [12], the
value of antigen results for PWE can be twofold: 1) assist in
diagnostic and treatment decisions as it can determine the
presence/absence of viable cysts; 2) improve the diagnostic
potential, especially in areas where neuroimaging techniques are
not available/accessible. It is obvious that Ag-ELISA as a stand
alone diagnostic technique cannot be sufficient for the detection of
NCC; the use of serological techniques alone is insufficient for this
diagnosis [32]. However, clearly more efforts should be put into
Figure 2. Sensitivity and complement of specificity of antigen ELISA detection of neurocysticercosis in people with epilepsy.
Receiver operator characteristic curve showing the relationship between sensitivity (true positive rate) and complement of specificity (false positive
rate) for antigen ELISA for the detection of neurocysticercosis in people with epilepsy.
doi:10.1371/journal.pntd.0001851.g002
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developing a set of revised diagnostic criteria based on multiple
diagnostic tools that can be implemented in resource-poor areas.
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